Synopsis: Alembic Pharmaceuticals Limited has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Dapsone Gel, 5%, a topical acne treatment. The approval, therapeutically equivalent to Almirall’s branded Aczone Gel, 5%, takes Alembic’s cumulative USFDA ANDA approvals to 244.
India’s generic pharmaceutical export sector continues to gain ground in the U.S. market, the world’s largest by prescription volume, as domestic manufacturers accumulate regulatory approvals across dermatology, oncology, and specialty segments.
USFDA final approvals for generic equivalents of established branded drugs represent direct revenue opportunities, allowing Indian companies to capture market share in products where brand exclusivity has lapsed. Dermatology, in particular, has emerged as a high-activity segment given the large addressable patient population for conditions such as acne vulgaris.
What’s the News?
Alembic Pharmaceuticals Limited has received final approval from the USFDA to market its generic version of Dapsone Gel (5%). This approval allows the company to sell a product that is medically identical to the brand-name drug, Aczone Gel (5%), which is currently marketed by Almirall, LLC. Officially used to treat acne vulgaris, Alembic reported this regulatory milestone to both the BSE and NSE on June 26, 2026, in compliance with standard market listing regulations.
Dapsone belongs to a class of medications known as sulfone antibiotics and is highly valued for its strong anti-inflammatory properties. It has a long, proven clinical track record of successfully clearing up painful, swollen pimples and mixed acne breakouts. By formulation, this 5% gel is designed to be applied directly onto the skin, which allows the medication to target acne where it starts while keeping the medicine from absorbing too heavily into the rest of the body.
While a final approval from the USFDA doesn’t automatically guarantee immediate cash flow, it hands Alembic the official green light to commercialize the medicine in the highly competitive U.S. market. According to IQVIA data, Dapsone Gel, 5% has an estimated market size of approximately US $ 18 million for the twelve months ending March 2026.
By securing the rights to sell a generic alternative to Aczone, Alembic gains direct entry into a lucrative slice of the skincare market with a ready-made audience of prescribing dermatologists. Exactly how much revenue this launch generates will ultimately depend on Alembic’s pricing strategy and the number of competing generics in the space, but offering a more affordable version of a trusted, high-demand acne treatment positions the company well to capture a meaningful market share.
This particular approval is a significant milestone because it further accelerates Alembic’s expansion into the high-margin topical dermatology market, building on their existing specialty pipeline. For a company that has invested heavily to build top-tier, U.S. compliant factories, getting products approved quickly is the smartest way to scale operational profitability.
This latest regulatory victory further strengthens the drugmaker’s international pipeline and commercial presence in the United States. With this latest nod, Alembic’s cumulative USFDA approval tally has officially reached 244 Abbreviated New Drug Applications (ANDAs). This total portfolio consists of 224 final approvals that are ready for the market, alongside 20 tentative approvals awaiting final clearance.
Following the announcement, shares of Alembic Pharmaceuticals Limited rose 1.89%, trading around ₹786.05. The company features a market capitalization of approximately ₹15,377 crore and is currently trading at a P/E ratio of 22.61.
Company Overview
Founded in 1907 and headquartered in Vadodara, Gujarat, Alembic Pharmaceuticals Limited is a vertically integrated, research-driven generic pharmaceutical company. The company manufactures and markets generic pharmaceutical products globally, with its research and manufacturing facilities approved by the USFDA and several other international regulatory authorities. Alembic is among India’s leading players in branded generics domestically, supported by a field force of over 5,500 medical representatives.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
